Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Fortress Biotech Inc's Business Segments
Fortress Biotech Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
2
Largest Segment
Journey
Total Revenue
$ 16
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Journey99.5%
- Fortress Biotech Inc0.5%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Journey | $ 16 | 99.5% |
| Fortress Biotech Inc | $ 0 | 0.5% |
Revenue by Product & Service Category - Q1 FY2026
- Emrosi39%
- Qbrexza31.4%
- Accutane20.7%
- Foam Franchise Products6.5%
- Other legacy product revenue1.7%
- Royalty0.5%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Emrosi | $ 6 | 39% |
| Qbrexza | $ 5 | 31.4% |
| Accutane | $ 3 | 20.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
3 more categories available
Sign in to unlock the full Fortress Biotech Inc dataset.
Description of Fortress Biotech Inc
Fortress Biotech Inc. is a biopharmaceutical company that operates as a diversified investment firm. It focuses on developing, acquiring, and commercializing innovative pharmaceutical and biotechnology products. The company was founded in 2006 and is headquartered in New York City, New York.
Fortress Biotech is primarily involved in the development of novel therapeutics across a wide range of medical areas, including oncology, rare diseases, gene therapy, cell therapy, and immunology. The company operates various subsidiary companies, each dedicated to a specific therapeutic focus, which allows for a diversified portfolio of products and technologies.
One of the key strategies of Fortress Biotech is its partnership model, where it collaborates with academic institutions, research organizations, and other biopharmaceutical companies to develop and commercialize promising drug candidates. It provides financial resources, infrastructure, and operational expertise to its subsidiary companies, allowing them to focus on their core research and development activities.
Fortress Biotech's subsidiary companies include Aevitas Therapeutics, developing gene therapies for rare genetic diseases; Avenue Therapeutics, working on the development of a non-opioid painkiller for postoperative pain; Caelum Biosciences, focusing on clinical-stage biologics for the treatment of cancer and autoimmune diseases; and Checkpoint Therapeutics, engaged in the development of immuno-oncology therapies.
The company also has partnerships with other biopharmaceutical companies and academic institutions, such as Cellvation, Mustang Bio, and Fortress Cell Therapeutics. These partnerships further enhance its research and development capabilities, allowing for the advancement of innovative therapies.
Fortress Biotech's success lies in its ability to leverage the expertise and resources of its subsidiary companies and partners to accelerate the development of new drugs and therapies. It aims to bring transformative medicines to patients with unmet medical needs, while also generating significant value for its stakeholders.
In addition to its drug development activities, Fortress Biotech also focuses on commercializing and marketing its approved products. The company has a dedicated team that handles the commercialization and distribution of its therapies, ensuring a successful launch and market penetration.
Overall, Fortress Biotech Inc. is a diversified biopharmaceutical company that is actively involved in the development, acquisition, and commercialization of innovative medicines. Through its partnership model and subsidiary companies, it strives to bring novel therapies to patients and create value for its shareholders.
Fortress Biotech is primarily involved in the development of novel therapeutics across a wide range of medical areas, including oncology, rare diseases, gene therapy, cell therapy, and immunology. The company operates various subsidiary companies, each dedicated to a specific therapeutic focus, which allows for a diversified portfolio of products and technologies.
One of the key strategies of Fortress Biotech is its partnership model, where it collaborates with academic institutions, research organizations, and other biopharmaceutical companies to develop and commercialize promising drug candidates. It provides financial resources, infrastructure, and operational expertise to its subsidiary companies, allowing them to focus on their core research and development activities.
Fortress Biotech's subsidiary companies include Aevitas Therapeutics, developing gene therapies for rare genetic diseases; Avenue Therapeutics, working on the development of a non-opioid painkiller for postoperative pain; Caelum Biosciences, focusing on clinical-stage biologics for the treatment of cancer and autoimmune diseases; and Checkpoint Therapeutics, engaged in the development of immuno-oncology therapies.
The company also has partnerships with other biopharmaceutical companies and academic institutions, such as Cellvation, Mustang Bio, and Fortress Cell Therapeutics. These partnerships further enhance its research and development capabilities, allowing for the advancement of innovative therapies.
Fortress Biotech's success lies in its ability to leverage the expertise and resources of its subsidiary companies and partners to accelerate the development of new drugs and therapies. It aims to bring transformative medicines to patients with unmet medical needs, while also generating significant value for its stakeholders.
In addition to its drug development activities, Fortress Biotech also focuses on commercializing and marketing its approved products. The company has a dedicated team that handles the commercialization and distribution of its therapies, ensuring a successful launch and market penetration.
Overall, Fortress Biotech Inc. is a diversified biopharmaceutical company that is actively involved in the development, acquisition, and commercialization of innovative medicines. Through its partnership model and subsidiary companies, it strives to bring novel therapies to patients and create value for its shareholders.
Fortress Biotech Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative drugs and therapies. The company operates through various segments, products, and services, aiming to address unmet medical needs in a variety of therapeutic areas.
Segments
1. Research and Development (R&D): Fortress Biotech has a strong emphasis on R&D, leveraging its proprietary technologies to develop new drug candidates. The focus areas include oncology, neurology, rare diseases, and infectious diseases. The company often collaborates with academic institutions and pharmaceutical partners to enhance its R&D capabilities.
2. Commercial Operations: Fortress engages in commercializing products either through its own marketing efforts or by partnering with established pharmaceutical companies. This segment is crucial for bringing new therapies to market and ensuring they reach the patients who need them.
3. Clinical Development: Fortress has a robust pipeline of clinical-stage biotech products. This segment involves conducting clinical trials to evaluate the safety and efficacy of new drugs, which is essential for regulatory approval.
Products
Fortress Biotech’s product portfolio comprises a diverse array of pharmaceutical agents and biologics. The company focuses on developing therapies that are in different stages of clinical development, including:
1. Oncology Products:
- Tumor Targeted Therapies: These products aim to specifically target cancer cells while sparing healthy tissues, enhancing treatment efficacy and reducing side effects.
- Immuno-oncology: Fortress develops therapies that stimulate or inhibit the immune system to fight cancer, leveraging the bodys natural defenses against tumors.
2. Neurology Products:
- Neurodegenerative Disease Treatments: These include therapies aimed at conditions such as Alzheimer’s and Parkinson’s diseases, focusing on slowing disease progression or alleviating symptoms.
- Pain Management: Fortress is involved in developing new analgesics that could provide better pain relief without the addictive properties of opioids.
3. Rare Disease Products:
- Enzyme Replacement Therapies: These therapies are designed to replace deficient enzymes in patients with rare genetic disorders, addressing the underlying causes of these conditions.
- Gene Therapies: Fortress also explores innovative gene therapy approaches for rare genetic diseases to provide potential cures.
4. Infectious Disease Products:
- Antiviral Drugs: The company develops treatments for viral infections, which may include monoclonal antibodies or antiviral agents targeting specific viruses.
- Vaccines: Research into vaccine development for various infectious diseases is also part of Fortress’s portfolio, contributing to public health initiatives.
Services
Fortress Biotech provides several services to support its R&D activities and commercialization efforts:
1. Clinical Trial Management: The company manages clinical trials from design to execution, including regulatory submissions, patient recruitment, and data management to ensure compliance with regulations.
2. Manufacturing and Supply Chain Services: Fortress Biotech engages in the production and distribution of its pharmaceutical products. This includes working with contract manufacturing organizations (CMOs) to ensure that products meet quality standards and are available in sufficient quantities for clinical trials and market launch.
3. Regulatory Consulting: The company offers services to navigate the complex regulatory environments required for bringing new drugs to market. This involves preparing and submitting documentation to regulatory agencies, as well as ensuring compliance throughout the product lifecycle.
4. Business Development: Fortress actively engages in partnerships and licensing agreements to enhance its product pipeline. This includes identifying and acquiring promising therapies from other biotech companies or academic institutions.
Overall, Fortress Biotech Inc. encompasses a wide range of activities across different segments, focusing on innovation in pharmaceuticals and biotechnology. Its commitment to developing therapies for serious medical conditions illustrates its role as a significant player in the biopharmaceutical industry.
Segments
1. Research and Development (R&D): Fortress Biotech has a strong emphasis on R&D, leveraging its proprietary technologies to develop new drug candidates. The focus areas include oncology, neurology, rare diseases, and infectious diseases. The company often collaborates with academic institutions and pharmaceutical partners to enhance its R&D capabilities.
2. Commercial Operations: Fortress engages in commercializing products either through its own marketing efforts or by partnering with established pharmaceutical companies. This segment is crucial for bringing new therapies to market and ensuring they reach the patients who need them.
3. Clinical Development: Fortress has a robust pipeline of clinical-stage biotech products. This segment involves conducting clinical trials to evaluate the safety and efficacy of new drugs, which is essential for regulatory approval.
Products
Fortress Biotech’s product portfolio comprises a diverse array of pharmaceutical agents and biologics. The company focuses on developing therapies that are in different stages of clinical development, including:
1. Oncology Products:
- Tumor Targeted Therapies: These products aim to specifically target cancer cells while sparing healthy tissues, enhancing treatment efficacy and reducing side effects.
- Immuno-oncology: Fortress develops therapies that stimulate or inhibit the immune system to fight cancer, leveraging the bodys natural defenses against tumors.
2. Neurology Products:
- Neurodegenerative Disease Treatments: These include therapies aimed at conditions such as Alzheimer’s and Parkinson’s diseases, focusing on slowing disease progression or alleviating symptoms.
- Pain Management: Fortress is involved in developing new analgesics that could provide better pain relief without the addictive properties of opioids.
3. Rare Disease Products:
- Enzyme Replacement Therapies: These therapies are designed to replace deficient enzymes in patients with rare genetic disorders, addressing the underlying causes of these conditions.
- Gene Therapies: Fortress also explores innovative gene therapy approaches for rare genetic diseases to provide potential cures.
4. Infectious Disease Products:
- Antiviral Drugs: The company develops treatments for viral infections, which may include monoclonal antibodies or antiviral agents targeting specific viruses.
- Vaccines: Research into vaccine development for various infectious diseases is also part of Fortress’s portfolio, contributing to public health initiatives.
Services
Fortress Biotech provides several services to support its R&D activities and commercialization efforts:
1. Clinical Trial Management: The company manages clinical trials from design to execution, including regulatory submissions, patient recruitment, and data management to ensure compliance with regulations.
2. Manufacturing and Supply Chain Services: Fortress Biotech engages in the production and distribution of its pharmaceutical products. This includes working with contract manufacturing organizations (CMOs) to ensure that products meet quality standards and are available in sufficient quantities for clinical trials and market launch.
3. Regulatory Consulting: The company offers services to navigate the complex regulatory environments required for bringing new drugs to market. This involves preparing and submitting documentation to regulatory agencies, as well as ensuring compliance throughout the product lifecycle.
4. Business Development: Fortress actively engages in partnerships and licensing agreements to enhance its product pipeline. This includes identifying and acquiring promising therapies from other biotech companies or academic institutions.
Overall, Fortress Biotech Inc. encompasses a wide range of activities across different segments, focusing on innovation in pharmaceuticals and biotechnology. Its commitment to developing therapies for serious medical conditions illustrates its role as a significant player in the biopharmaceutical industry.